SEN 1269

Pricing Availability   Qty
Cat.No. 4699 - SEN 1269 | CAS No. 956128-01-1
Description: Amyloid-β aggregation inhibitor
Chemical Name: 3-[[5-[3-(Dimethylamino)phenoxy]-2-pyrimidinyl]amino]phenol
Purity: ≥98% (HPLC)

Biological Activity

Amyloid-β (Aβ) aggregation inhibitor; blocks Aβ(1-42) aggregation and protects neuronal cell lines exposed to Aβ(1-42). Reduces Aβ oligomer-induced LTP and memory deficits in vivo.

Compound Libraries

SEN 1269 is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 322.36
Formula C18H18N4O2
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 956128-01-1
PubChem ID 46835756
Smiles OC1=CC(NC2=NC=C(OC3=CC=CC(N(C)C)=C3)C=N2)=CC=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 32.24 100
ethanol 16.12 50

Preparing Stock Solutions

The following data is based on the product molecular weight 322.36. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.1 mL 15.51 mL 31.02 mL
5 mM 0.62 mL 3.1 mL 6.2 mL
10 mM 0.31 mL 1.55 mL 3.1 mL
50 mM 0.06 mL 0.31 mL 0.62 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:


References are publications that support the biological activity of the product.

Scopes et al (2012) Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity. Br.J.Pharmacol. 167 383 PMID: 22913627

If you know of a relevant reference for SEN 1269, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Amyloid β Peptide Inhibitors

Keywords: SEN 1269, SEN 1269 supplier, SEN1269, Amyloid-β, (Aβ), aggregation, inhibitors, inhibits, LTP, memory, Alzheimer's, amyloidbeta, amyloidb, Amyloid, Beta, Peptides, 4699, Tocris Bioscience

Citations for SEN 1269

Citations are publications that use Tocris products.

Currently there are no citations for SEN 1269. Do you know of a great paper that uses SEN 1269 from Tocris? Please let us know.

Reviews for SEN 1269

There are currently no reviews for this product. Be the first to review SEN 1269 and earn rewards!

Have you used SEN 1269?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.